Sugi Predict

Sugi Predict / Compounds / SCHEMBL22290685

SCHEMBL22290685

SCHEMBL22290685

CC(C)(C)OC(=O)c1ccn(S(C)(=O)=O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44
▸ PKM P14618 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ STAT3 P40763 2/20 0.35
▸ GABRA1 P14867 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA3 P34903 1/20 0.34
▸ GABRA2 P47869 1/20 0.34
▸ MET P08581 1/20 0.34
▸ TUBB4A P04350 1/20 0.33
▸ TUBB P07437 1/20 0.33
▸ TUBA3C P0DPH7 1/20 0.33
▸ TUBA1B P68363 1/20 0.33
▸ TUBA4A P68366 1/20 0.33
▸ TUBB4B P68371 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9918736 0.80 ALDH1A1 (0.50) CA12CA1CA2CA9CA14
SCHEMBL27556525 0.76 CA12 (0.45) CA12CA1CA2CA9CA14
SCHEMBL15180434 0.76 CA12 (0.41) CA12CA1CA2CA9CA14
SCHEMBL23705578 0.75 PKM (0.62) PKMALDH1A1TUBB4ATUBBTUBA3C
SCHEMBL21241997 0.75 PKM (0.49) CA12CA1CA2CA9CA14
SCHEMBL22306542 0.74 PKM (0.44) CA12CA1CA2CA9CA14
SCHEMBL23261369 0.73 POLB (0.47) PKMTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL22290741 0.72 CA12 (0.39) CA12CA1CA2CA9CA14
SCHEMBL24049473 0.72 CA12 (0.39) CA12CA1CA2CA9CA14
SCHEMBL34469716 0.72 CA12 (0.39) CA12CA1CA2CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486262-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-12-02 — — US disclosed
US-12383555-B2 Methods of treating cancers FOGHORN THERAPEUTICS INC. (US) 2025-08-12 — — US disclosed
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 — — EP disclosed
US-20240374605-A1 METHODS OF TREATING CANCER FOGHORN THERAPEUTICS INC. 2024-11-14 — — US disclosed
CN-113645971-B Compounds and uses thereof 福宏治疗公司 2024-10-18 — — CN disclosed
US-20240189318-A1 THERAPEUTIC REGIMENS OF AN INHIBITOR OF THE ENZYMATIC ACTIVITY OF BRG1 AND BRM FOGHORN THERAPEUTICS INC. 2024-06-13 — — US disclosed
EP-4376886-A2 METHODS OF TREATING CANCER Foghorn Therapeutics Inc. (US) 2024-06-05 — — EP disclosed
CN-118043053-A Methods of treating cancer 福宏治疗公司 2024-05-14 — — CN disclosed
US-20240101550-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-03-28 — — US disclosed
EP-4308124-A1 THERAPEUTIC REGIMENS OF AN INHIBITOR OF THE ENZYMATIC ACTIVITY OF BRG1 AND BRM Foghorn Therapeutics Inc. (US) 2024-01-24 — — EP disclosed
WO-2021236080-A1 METHODS OF TREATING CANCERS FOGHORN THERAPEUTICS INC. (US) 2021-11-25 — — WO disclosed
WO-2021236080-A1 METHODS OF TREATING CANCERS FOGHORN THERAPEUTICS INC. (US) 2021-11-25 — — WO disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 — — CN disclosed
WO-2021155264-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed
WO-2021155264-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed
WO-2021155262-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed
WO-2021155262-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed
US-20210230154-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-07-29 — — US disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 — — WO disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240189318-A1 THERAPEUTIC REGIMENS OF AN INHIBITOR OF THE ENZYMATIC ACTIVITY OF BRG1 AND BRM SMARCE1, RBBP7, SMARCB1 CA12 3708/4885CA1 2813/4885CA2 4240/4885
US-20210230154-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CA12 4343/4885CA1 4780/4885CA2 4715/4885
US-20240374605-A1 METHODS OF TREATING CANCER CARM1, SMARCC1, RB1 CA12 1664/4885CA1 1294/4885CA2 2764/4885
US-12486262-B2 Compounds and uses thereof VHL, CLN6, TFEB CA12 4343/4885CA1 4780/4885CA2 4715/4885
US-20240101550-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CA12 4343/4885CA1 4780/4885CA2 4715/4885
US-12383555-B2 Methods of treating cancers MCL1, BRPF3, VHL CA12 1320/4885CA1 2056/4885CA2 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.